Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[ d ]isoxazole-containing androgen receptor modulators

Journal of Medicinal Chemistry

Volumn 55, Issue 14, 2012, Pages 6316-6327

  Poutiainen, Pekka K ^a   Oravilahti, Tuomas ^a   Peräkylä, Mikael ^a   Palvimo, Jorma J ^a   Ihalainen, Janne A ^b   Laatikainen, Reino ^a   Pulkkinen, Juha T ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF JYVÄSKYLÄ   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3A,4,5,6,7,7A HEXAHYDROBENZO[D]ISOXAZOL 3 YL) 2 (TRIFLUOROMETHYL)BENZONITRILE; ANDROGEN RECEPTOR; BICALUTAMIDE; CYCLOALKANE DERIVATIVE; CYCLOOCTANE DERIVATIVE; HYDROXYFLUTAMIDE; ISOXAZOLE DERIVATIVE; RADIOLIGAND; SELECTIVE ANDROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING COMPETITION; CANCER PATIENT; CELL STRAIN COS1; CONTROLLED STUDY; DRUG BINDING SITE; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR LIBRARY; MOLECULAR MODEL; MUTANT; PHARMACOPHORE; PROSTATE CANCER; REPORTER GENE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CERCOPITHECUS AETHIOPS; CHEMISTRY TECHNIQUES, SYNTHETIC; COS CELLS; CYCLOPARAFFINS; DRUG DESIGN; ISOXAZOLES; MODELS, MOLECULAR; NONSTEROIDAL ANTI-ANDROGENS; PROTEIN CONFORMATION; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84864220496     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300233k     Document Type: Article

References (67)

1. Mooradian, A. D.; Morley, J. E.; Korenman, S. G. Biological actions of androgens Endocr. Rev. 1987, 8, 1-28
2. Mangelsdorf, D. J.; Thummel, C.; Beato, M.; Herrlich, P.; Schutz, G.; Umesono, K.; Blumberg, B.; Kastner, P.; Mark, M.; Chambon, P.; Evans, R. M. The nuclear receptor superfamily: the second decade Cell 1995, 83, 835-839
3. Sar, M.; Lubahn, D. B.; French, F. S.; Wilson, E. M. Immunohistochemical localization of the androgen receptor in rat and human tissues Endocrinology 1990, 127, 3180-3186
4. Gao, W.; Bohl, C. E.; Dalton, J. T. Chemistry and structural biology of androgen receptor Chem. Rev. 2005, 105, 3352-3370
5. Heinlein, C. A.; Chang, C. Androgen receptor in prostate cancer Endocr. Rev. 2004, 25, 276-308
6. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics Ca-Cancer J. Clin. 2011, 61, 69-90
7. Klotz, L. Maximal androgen blockade for advanced prostate cancer Best Pract. Res. Clin. Endocrinol. Metab. 2008, 22, 331-340
8. Labrie, F.; Dupont, A.; Belanger, A.; Cusan, L.; Lacourciere, Y.; Monfette, G.; Laberge, J. G.; Emond, J. P.; Fazekas, A. T.; Raynaud, J. P.; Husson, J. M. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen Clin. Invest. Med. 1982, 5, 267-275
9. Mohler, M. L.; Bohl, C. E.; Jones, A.; Coss, C. C.; Narayanan, R.; He, Y.; Hwang, D. J.; Dalton, J. T.; Miller, D. D. Nonsteroidal selective androgen receptor modulators (SARMs): dissociating the anabolic and androgenic activities of the androgen receptor for therapeutic benefit J. Med. Chem. 2009, 52, 3597-3617
10. Haendler, B.; Cleve, A. Recent developments in antiandrogens and selective androgen receptor modulators Mol. Cell. Endocrinol. 2012, 352, 79-91
11. Narayanan, R.; Mohler, M. L.; Bohl, C. E.; Miller, D. D.; Dalton, J. T. Selective androgen receptor modulators in preclinical and clinical development Nucl. Recept. Signaling 2008, 6, e010
12. Brown, T. R. Nonsteroidal selective androgen receptors modulators (SARMs): designer androgens with flexible structures provide clinical promise Endocrinology 2004, 145, 5417-5419
13. Zhang, X.; Li, X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S. G.; Sui, Z. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators J. Med. Chem. 2007, 50, 3857-3869
14. Zhao, S.; Shen, Y.; van Oeveren, A.; Marschke, K. B.; Zhi, L. Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones Bioorg. Med. Chem. Lett. 2008, 18, 3431-3435
15. Zhou, C.; Wu, G.; Feng, Y.; Li, Q.; Su, H.; Mais, D. E.; Zhu, Y.; Li, N.; Deng, Y.; Yang, D.; Wang, M. W. Discovery and biological characterization of a novel series of androgen receptor modulators Br. J. Pharmacol. 2008, 154, 440-450
16. Long, Y. O.; Higuchi, R. I.; Caferro, T. R.; Lau, T. L.; Wu, M.; Cummings, M. L.; Martinborough, E. A.; Marschke, K. B.; Chang, W. Y.; Lopez, F. J.; Karanewsky, D. S.; Zhi, L. Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity Bioorg. Med. Chem. Lett. 2008, 18, 2967-2971
17. Piu, F.; Gardell, L. R.; Son, T.; Schlienger, N.; Lund, B. W.; Schiffer, H. H.; Vanover, K. E.; Davis, R. E.; Olsson, R.; Bradley, S. R. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator J. Steroid Biochem. Mol. Biol. 2008, 109, 129-137
18. Ohta, K.; Goto, T.; Fijii, S.; Suzuki, T.; Ohta, S.; Endo, Y. Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring Bioorg. Med. Chem. 2008, 16, 8022-8028
19. Nirschl, A. A.; Zou, Y.; Krystek, S. R., Jr; Sutton, J. C.; Simpkins, L. M.; Lupisella, J. A.; Kuhns, J. E.; Seethala, R.; Golla, R.; Sleph, P. G.; Beehler, B. C.; Grover, G. J.; Egan, D.; Fura, A.; Vyas, V. P.; Li, Y. X.; Sack, J. S.; Kish, K. F.; An, Y.; Bryson, J. A.; Gougoutas, J. Z.; DiMarco, J.; Zahler, R.; Ostrowski, J.; Hamann, L. G. N -Aryloxazolidin-2-imine muscle selective androgen receptor modulators enhance potency through pharmacophore reorientation J. Med. Chem. 2009, 52, 2794-2798
20. Schlienger, N.; Lund, B. W.; Pawlas, J.; Badalassi, F.; Bertozzi, F.; Lewinsky, R.; Fejzic, A.; Thygesen, M. B.; Tabatabaei, A.; Bradley, S. R.; Gardell, L. R.; Piu, F.; Olsson, R. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators J. Med. Chem. 2009, 52, 7186-7191
21. Miller, C. P.; Bhaket, P.; Muthukaman, N.; Lyttle, C. R.; Shomali, M.; Gallacher, K.; Slocum, C.; Hattersley, G. Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs) Bioorg. Med. Chem. Lett. 2010, 20, 7516-7520
22. Zilbermint, M. F.; Dobs, A. S. Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia Fut. Oncol. 2009, 5, 1211-1220
23. Ostrowski, J.; Kuhns, J. E.; Lupisella, J. A.; Manfredi, M. C.; Beehler, B. C.; Krystek, S. R., Jr; Bi, Y.; Sun, C.; Seethala, R.; Golla, R.; Sleph, P. G.; Fura, A.; An, Y.; Kish, K. F.; Sack, J. S.; Mookhtiar, K. A.; Grover, G. J.; Hamann, L. G. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats Endocrinology 2007, 148, 4-12
24. Narayanan, R.; Coss, C. C.; Yepuru, M.; Kearbey, J. D.; Miller, D. D.; Dalton, J. T. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways Mol. Endocrinol. 2008, 22, 2448-2465
25. Hanada, K.; Furuya, K.; Yamamoto, N.; Nejishima, H.; Ichikawa, K.; Nakamura, T.; Miyakawa, M.; Amano, S.; Sumita, Y.; Oguro, N. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis Biol. Pharm. Bull. 2003, 26, 1563-1569
26. Sun, C.; Robl, J. A.; Wang, T. C.; Huang, Y.; Kuhns, J. E.; Lupisella, J. A.; Beehler, B. C.; Golla, R.; Sleph, P. G.; Seethala, R.; Fura, A.; Krystek, S. R., Jr; An, Y.; Malley, M. F.; Sack, J. S.; Salvati, M. E.; Grover, G. J.; Ostrowski, J.; Hamann, L. G. Discovery of potent, orally active, and muscle-selective androgen receptor modulators based on an N - arylhydroxybicyclohydantoin scaffold J. Med. Chem. 2006, 49, 7596-7599
27. Allan, G. F.; Tannenbaum, P.; Sbriscia, T.; Linton, O.; Lai, M. T.; Haynes-Johnson, D.; Bhattacharjee, S.; Zhang, X.; Sui, Z.; Lundeen, S. G. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats Endocrine 2007, 32, 41-51
28. Vajda, E. G.; Lopez, F. J.; Rix, P.; Hill, R.; Chen, Y.; Lee, K. J.; O'Brien, Z.; Chang, W. Y.; Meglasson, M. D.; Lee, Y. H. Pharmacokinetics and pharmacodynamics of LGD-3303 [9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl) -3H-pyrrolo-[3,2-f]quinolin-7(6H)-one], an orally available nonsteroidal- selective androgen receptor modulator J. Pharmacol. Exp. Ther. 2009, 328, 663-670
29. Dayger, C.; Villasana, L.; Pfankuch, T.; Davis, M.; Raber, J. Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice Brain Res. 2011, 1381, 134-140
30. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6201-6206
31. Chen, Y.; Clegg, N. J.; Scher, H. I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 2009, 10, 981-991
32. Taplin, M. E. Drug insight: role of the androgen receptor in the development and progression of prostate cancer Nat. Clin. Pract. Oncol. 2007, 4, 236-244
33. Buchanan, G.; Greenberg, N. M.; Scher, H. I.; Harris, J. M.; Marshall, V. R.; Tilley, W. D. Collocation of androgen receptor gene mutations in prostate cancer Clin. Cancer Res. 2001, 7, 1273-1281
34. Wilding, G.; Chen, M.; Gelmann, E. P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens Prostate 1989, 14, 103-115
35. Chen, C. D.; Welsbie, D. S.; Tran, C.; Baek, S. H.; Chen, R.; Vessella, R.; Rosenfeld, M. G.; Sawyers, C. L. Molecular determinants of resistance to antiandrogen therapy Nat. Med. 2004, 10, 33-39
36. Knudsen, K. E.; Penning, T. M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 2010, 21, 315-24
37. Attard, G; Cooper, C. S.; de Bono, J. S. Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 2009, 16, 458-462
38. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324, 787-790
39. Scher, H. I.; Beer, T. M.; Higano, C. S.; Anand, A.; Taplin, M. E.; Efstathiou, E.; Rathkopf, D.; Shelkey, J.; Yu, E. Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; Morris, M. J.; Danila, D. C.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C. L. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase 1-2 Study Lancet 2010, 375, 1437-1446
40. Yamamoto, S.; Matsunaga, N.; Hitaka, T.; Yamada, M.; Hara, T.; Miyazaki, J.; Santou, T.; Kusaka, M.; Yamaoka, M.; Kanzaki, N.; Furuya, S.; Tasaka, A.; Hamamura, K.; Ito, M. Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists Bioorg. Med. Chem. 2012, 20, 422-434
41. Guo, C.; Kephart, S.; Ornelas, M.; Gonzalez, J.; Linton, A.; Pairish, M.; Nagata, A.; Greasley, S.; Elleraas, J.; Hosea, N.; Engebretsen, J.; Fanjul, A. N. Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer Bioorg. Med. Chem. Lett. 2012, 22, 1230-1236
42. Guo, C.; Pairish, M.; Linton, A.; Kephart, S.; Ornelas, M.; Nagata, A.; Burke, B.; Dong, L.; Engebretsen, J.; Fanjul, A. N. Design of Oxobenzimidazoles and Oxindoles as Novel Androgen Receptor Antagonists Bioorg. Med. Chem. Lett. 2012, 22, 2572-2578
43. Pulkkinen, J. T.; Honkakoski, P.; Perakyla, M.; Berczi, I.; Laatikainen, R. Synthesis and evaluation of estrogen agonism of diaryl 4,5-dihydroisoxazoles, 3-hydroxyketones, 3-methoxyketones, and 1,3-diketones: a compound set forming a 4D molecular library J. Med. Chem. 2008, 51, 3562-3571
44. Poutiainen, P. K.; Venalainen, T. A.; Perakyla, M.; Matilainen, J. M.; Vaisanen, S.; Honkakoski, P.; Laatikainen, R.; Pulkkinen, J. T. Synthesis and biological evaluation of phenolic 4,5-dihydroisoxazoles and 3-hydroxy ketones as estrogen receptor alpha and beta agonists Bioorg. Med. Chem. 2010, 18, 3437-3447
45. Makkonen, H.; Jaaskelainen, T.; Rytinki, M. M.; Palvimo, J. J. Analysis of androgen receptor activity by reporter gene assays Methods Mol. Biol. 2011, 776, 71-80
46. Thompson, J.; Saatcioglu, F.; Janne, O. A.; Palvimo, J. J. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity Mol. Endocrinol. 2001, 15, 923-935
47. Furr, B. J.; Valcaccia, B.; Curry, B.; Woodburn, J. R.; Chesterson, G.; Tucker, H. ICI 176,334: a novel non-steroidal, peripherally selective antiandrogen J. Endocrinol. 1987, 113, R7-9
48. Neri, R.; Florance, K.; Koziol, P.; Van Cleave, S. A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4′-nitro-3′- trifluoromethylisobutyranilide) Endocrinology 1972, 91, 427-437
49. Hankovsky, O. H.; Hideg, K.; Lovas, M. J. Synthesis and reaction of ortho-fluoronitroaryl nitroxides. Novel versatile synthons and reagents for spin-labelling studies Can. J. Chem. 1989, 67, 1392
50. Li, H. Y.; DeLucca, I.; Boswell, G. A.; Billheimer, J. T.; Drummond, S.; Gillies, P. J.; Robinson, C. Design, synthesis and structure-activity relationship studies of novel 4,4-bis(trifluoromethyl)imidazolines as acyl-CoA: cholesterol acyltransferase (ACAT) inhibitors and antihypercholesterolemic agents Bioorg. Med. Chem. 1997, 5, 1345-1361
51. Bergerat, J. P.; Ceraline, J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer Hum. Mutat. 2009, 30, 145-157
52. Brooke, G. N.; Bevan, C. L. The role of androgen receptor mutations in prostate cancer progression Curr. Genomics 2009, 10, 18-25
53. Koochekpour, S. Androgen receptor signaling and mutations in prostate cancer Asian J. Androl. 2010, 12, 639-657
54. Leitao, J. M.; Esteves da Silva, J. C. Firefly luciferase inhibition J. Photochem. Photobiol. B 2010, 101, 1-8
55. Bakhtiarova, A.; Taslimi, P.; Elliman, S. J.; Kosinski, P. A.; Hubbard, B.; Kavana, M.; Kemp, D. M. Resveratrol inhibits firefly luciferase Biochem. Biophys. Res. Commun. 2006, 351, 481-484
56. GraphPad Prism version 5.03 for Windows, GraphPad Software, San Diego, CA.
57. Hur, E.; Pfaff, S. J.; Payne, E. S.; Gron, H.; Buehrer, B. M.; Fletterick, R. J. Recognition and accommodation at the androgen receptor coactivator binding interface PLoS Biol. 2004, 2, E274
58. Bohl, C. E.; Gao, W.; Miller, D. D.; Bell, C. E.; Dalton, J. T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 6201-6206
59. Bohl, C. E.; Miller, D. D.; Chen, J.; Bell, C. E.; Dalton, J. T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor J. Biol. Chem. 2005, 280, 37747-37754
60. Case, D. A.; Darden, T. A.; Cheatham, T. E. I.; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza., P.; Mathews, H. D.; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER 9, 2006.
61. Hornak, V.; Abel, R.; Okur, A.; Strockbine, B.; Roitberg, A.; Simmerling, C. Comparison of multiple Amber force fields and development of improved protein backbone parameters Proteins 2006, 65, 712-725
62. Accelrys Discovery Studio software version 1.7, Anonymous Accelrys Software Inc., 2005-06.
63. Autschbach, J; Ziegler, T; van Gisbergen, S. J. A.; Baerends, E. J. Chiroptical properties from time-dependent density functional theory. I. Circular dichroism spectra of organic molecules J. Chem. Phys. 2002, 116, 6930-40
64. Scalmani, G.; Frisch, M. J.; Mennucci, B.; Tomasi, J.; Cammi, R.; Barone, V. Geometries and properties of excited states in the gas phase and in solution: Theory and application of a time-dependent density functional theory polarizable continuum model J. Chem. Phys. 2006, 124, 1-15
65. Tomasi, J.; Mennucci, B.; Cammi, R. Quantum mechanical continuum solvation models Chem. Rev. 2005, 105, 2999-3093
66. Bruhn, T.; Schaumlöffel, A.; Hemberger, Y.; Bringmann, G. SpecDis version 1.53, University of Wuerzburg, Germany, 2012.
67. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian 09 Revision C.01, Gaussian, Inc., Wallingford, CT, 2011.